世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

膣炎診断薬-世界市場シェアとランキング、全体売上高と需要予測 2025-2031

膣炎診断薬-世界市場シェアとランキング、全体売上高と需要予測 2025-2031


Vaginitis Diagnostics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

膣炎診断薬の世界市場は、2024年には100万米ドル規模と推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年の年平均成長率は%になると予測されている。 膣炎診断とは、膣の炎症や感染症である... もっと見る

 

 

出版社 出版年月 電子版価格 納期 言語
QYResearch
QYリサーチ
2025年3月21日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
5-7営業日 英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

膣炎診断薬の世界市場は、2024年には100万米ドル規模と推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年の年平均成長率は%になると予測されている。

膣炎診断とは、膣の炎症や感染症である膣炎を診断するために医療従事者が使用する方法や手順を指します。膣炎の診断は、根本的な原因を特定し、適切な治療を提供するために不可欠である。

世界の医薬品市場は2022年に1475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤がある。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。

本レポートは、膣炎診断薬の世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別の膣炎診断薬の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。
膣炎診断薬の市場規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データと予測データを売上高(百万ドル)で提供しています。定量的、定性的な分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場でのポジションを分析し、膣炎診断薬に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
アボット・ラボラトリーズ
アトリダ
ベクトン・ディッキンソン・アンド・カンパニー
セファイド(ダナハー社)
F.ホフマン・ラ・ロシュ社
ホロジック
ラボラトリー・コーポレーション・オブ・アメリカ・ホールディングス
QIAGEN
クエスト・ダイアグノスティックス
クィデル・コーポレーション
タイプ別セグメント
核酸増幅アッセイ
DNAプローブ
臨床検査
アプリケーション別
病院
専門クリニック
その他
地域別
北米
米国
カナダ
アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア太平洋地域
ヨーロッパ
ドイツ
フランス
英国
イタリア
オランダ
北欧諸国
その他のヨーロッパ
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他のMEA

各章の概要
第1章: レポートのスコープ、世界の総市場規模を紹介します。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:膣炎診断薬企業の競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:各市場セグメントの市場規模と発展の可能性をカバーし、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つけるのを助けるために、タイプ別に様々な市場セグメントの分析を提供します。
第4章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展の可能性をカバーし、読者が異なる川下市場のブルーオーシャン市場を見つけるのに役立ちます。
第5章:地域レベルでの膣炎診断薬の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。
第6章:国別膣炎診断薬の収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。
第7章:主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 Vaginitis Diagnostics Product Introduction
1.2 Global Vaginitis Diagnostics Market Size Forecast (2020-2031)
1.3 Vaginitis Diagnostics Market Trends & Drivers
1.3.1 Vaginitis Diagnostics Industry Trends
1.3.2 Vaginitis Diagnostics Market Drivers & Opportunity
1.3.3 Vaginitis Diagnostics Market Challenges
1.3.4 Vaginitis Diagnostics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Vaginitis Diagnostics Players Revenue Ranking (2024)
2.2 Global Vaginitis Diagnostics Revenue by Company (2020-2025)
2.3 Key Companies Vaginitis Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Vaginitis Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Vaginitis Diagnostics
2.6 Vaginitis Diagnostics Market Competitive Analysis
2.6.1 Vaginitis Diagnostics Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Vaginitis Diagnostics Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaginitis Diagnostics as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Nucleic Acid Amplification Assays
3.1.2 DNA Probe
3.1.3 Clinical Test
3.2 Global Vaginitis Diagnostics Sales Value by Type
3.2.1 Global Vaginitis Diagnostics Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Vaginitis Diagnostics Sales Value, by Type (2020-2031)
3.2.3 Global Vaginitis Diagnostics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Specialty Clinics
4.1.3 Others
4.2 Global Vaginitis Diagnostics Sales Value by Application
4.2.1 Global Vaginitis Diagnostics Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Vaginitis Diagnostics Sales Value, by Application (2020-2031)
4.2.3 Global Vaginitis Diagnostics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Vaginitis Diagnostics Sales Value by Region
5.1.1 Global Vaginitis Diagnostics Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Vaginitis Diagnostics Sales Value by Region (2020-2025)
5.1.3 Global Vaginitis Diagnostics Sales Value by Region (2026-2031)
5.1.4 Global Vaginitis Diagnostics Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Vaginitis Diagnostics Sales Value, 2020-2031
5.2.2 North America Vaginitis Diagnostics Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Vaginitis Diagnostics Sales Value, 2020-2031
5.3.2 Europe Vaginitis Diagnostics Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Vaginitis Diagnostics Sales Value, 2020-2031
5.4.2 Asia Pacific Vaginitis Diagnostics Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Vaginitis Diagnostics Sales Value, 2020-2031
5.5.2 South America Vaginitis Diagnostics Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Vaginitis Diagnostics Sales Value, 2020-2031
5.6.2 Middle East & Africa Vaginitis Diagnostics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Vaginitis Diagnostics Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Vaginitis Diagnostics Sales Value, 2020-2031
6.3 United States
6.3.1 United States Vaginitis Diagnostics Sales Value, 2020-2031
6.3.2 United States Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Vaginitis Diagnostics Sales Value, 2020-2031
6.4.2 Europe Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Vaginitis Diagnostics Sales Value, 2020-2031
6.5.2 China Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.5.3 China Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Vaginitis Diagnostics Sales Value, 2020-2031
6.6.2 Japan Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Vaginitis Diagnostics Sales Value, 2020-2031
6.7.2 South Korea Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Vaginitis Diagnostics Sales Value, 2020-2031
6.8.2 Southeast Asia Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Vaginitis Diagnostics Sales Value, 2020-2031
6.9.2 India Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.9.3 India Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Profile
7.1.2 Abbott Laboratories Main Business
7.1.3 Abbott Laboratories Vaginitis Diagnostics Products, Services and Solutions
7.1.4 Abbott Laboratories Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.1.5 Abbott Laboratories Recent Developments
7.2 Atrida
7.2.1 Atrida Profile
7.2.2 Atrida Main Business
7.2.3 Atrida Vaginitis Diagnostics Products, Services and Solutions
7.2.4 Atrida Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.2.5 Atrida Recent Developments
7.3 Becton, Dickinson and Company
7.3.1 Becton, Dickinson and Company Profile
7.3.2 Becton, Dickinson and Company Main Business
7.3.3 Becton, Dickinson and Company Vaginitis Diagnostics Products, Services and Solutions
7.3.4 Becton, Dickinson and Company Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.3.5 Becton, Dickinson and Company Recent Developments
7.4 Cepheid (Danaher Corporation)
7.4.1 Cepheid (Danaher Corporation) Profile
7.4.2 Cepheid (Danaher Corporation) Main Business
7.4.3 Cepheid (Danaher Corporation) Vaginitis Diagnostics Products, Services and Solutions
7.4.4 Cepheid (Danaher Corporation) Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.4.5 Cepheid (Danaher Corporation) Recent Developments
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 F. Hoffmann-La Roche Ltd. Profile
7.5.2 F. Hoffmann-La Roche Ltd. Main Business
7.5.3 F. Hoffmann-La Roche Ltd. Vaginitis Diagnostics Products, Services and Solutions
7.5.4 F. Hoffmann-La Roche Ltd. Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.6 Hologic, Inc.
7.6.1 Hologic, Inc. Profile
7.6.2 Hologic, Inc. Main Business
7.6.3 Hologic, Inc. Vaginitis Diagnostics Products, Services and Solutions
7.6.4 Hologic, Inc. Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.6.5 Hologic, Inc. Recent Developments
7.7 Laboratory Corporation of America Holdings
7.7.1 Laboratory Corporation of America Holdings Profile
7.7.2 Laboratory Corporation of America Holdings Main Business
7.7.3 Laboratory Corporation of America Holdings Vaginitis Diagnostics Products, Services and Solutions
7.7.4 Laboratory Corporation of America Holdings Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.7.5 Laboratory Corporation of America Holdings Recent Developments
7.8 QIAGEN
7.8.1 QIAGEN Profile
7.8.2 QIAGEN Main Business
7.8.3 QIAGEN Vaginitis Diagnostics Products, Services and Solutions
7.8.4 QIAGEN Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.8.5 QIAGEN Recent Developments
7.9 Quest Diagnostics Incorporated
7.9.1 Quest Diagnostics Incorporated Profile
7.9.2 Quest Diagnostics Incorporated Main Business
7.9.3 Quest Diagnostics Incorporated Vaginitis Diagnostics Products, Services and Solutions
7.9.4 Quest Diagnostics Incorporated Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.9.5 Quest Diagnostics Incorporated Recent Developments
7.10 Quidel Corporation
7.10.1 Quidel Corporation Profile
7.10.2 Quidel Corporation Main Business
7.10.3 Quidel Corporation Vaginitis Diagnostics Products, Services and Solutions
7.10.4 Quidel Corporation Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.10.5 Quidel Corporation Recent Developments
8 Industry Chain Analysis
8.1 Vaginitis Diagnostics Industrial Chain
8.2 Vaginitis Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Vaginitis Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Vaginitis Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

The global market for Vaginitis Diagnostics was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

Vaginitis diagnostics refer to the methods and procedures used by healthcare providers to diagnose vaginitis, which is the inflammation or infection of the vagina. Diagnosing vaginitis is essential to identify the underlying cause and provide appropriate treatment.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Vaginitis Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Vaginitis Diagnostics by region & country, by Type, and by Application.
The Vaginitis Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaginitis Diagnostics.

Market Segmentation
By Company
Abbott Laboratories
Atrida
Becton, Dickinson and Company
Cepheid (Danaher Corporation)
F. Hoffmann-La Roche Ltd.
Hologic, Inc.
Laboratory Corporation of America Holdings
QIAGEN
Quest Diagnostics Incorporated
Quidel Corporation
Segment by Type
Nucleic Acid Amplification Assays
DNA Probe
Clinical Test
Segment by Application
Hospitals
Specialty Clinics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Vaginitis Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Vaginitis Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Vaginitis Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Vaginitis Diagnostics Product Introduction
1.2 Global Vaginitis Diagnostics Market Size Forecast (2020-2031)
1.3 Vaginitis Diagnostics Market Trends & Drivers
1.3.1 Vaginitis Diagnostics Industry Trends
1.3.2 Vaginitis Diagnostics Market Drivers & Opportunity
1.3.3 Vaginitis Diagnostics Market Challenges
1.3.4 Vaginitis Diagnostics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Vaginitis Diagnostics Players Revenue Ranking (2024)
2.2 Global Vaginitis Diagnostics Revenue by Company (2020-2025)
2.3 Key Companies Vaginitis Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Vaginitis Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Vaginitis Diagnostics
2.6 Vaginitis Diagnostics Market Competitive Analysis
2.6.1 Vaginitis Diagnostics Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Vaginitis Diagnostics Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaginitis Diagnostics as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Nucleic Acid Amplification Assays
3.1.2 DNA Probe
3.1.3 Clinical Test
3.2 Global Vaginitis Diagnostics Sales Value by Type
3.2.1 Global Vaginitis Diagnostics Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Vaginitis Diagnostics Sales Value, by Type (2020-2031)
3.2.3 Global Vaginitis Diagnostics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Specialty Clinics
4.1.3 Others
4.2 Global Vaginitis Diagnostics Sales Value by Application
4.2.1 Global Vaginitis Diagnostics Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Vaginitis Diagnostics Sales Value, by Application (2020-2031)
4.2.3 Global Vaginitis Diagnostics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Vaginitis Diagnostics Sales Value by Region
5.1.1 Global Vaginitis Diagnostics Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Vaginitis Diagnostics Sales Value by Region (2020-2025)
5.1.3 Global Vaginitis Diagnostics Sales Value by Region (2026-2031)
5.1.4 Global Vaginitis Diagnostics Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Vaginitis Diagnostics Sales Value, 2020-2031
5.2.2 North America Vaginitis Diagnostics Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Vaginitis Diagnostics Sales Value, 2020-2031
5.3.2 Europe Vaginitis Diagnostics Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Vaginitis Diagnostics Sales Value, 2020-2031
5.4.2 Asia Pacific Vaginitis Diagnostics Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Vaginitis Diagnostics Sales Value, 2020-2031
5.5.2 South America Vaginitis Diagnostics Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Vaginitis Diagnostics Sales Value, 2020-2031
5.6.2 Middle East & Africa Vaginitis Diagnostics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Vaginitis Diagnostics Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Vaginitis Diagnostics Sales Value, 2020-2031
6.3 United States
6.3.1 United States Vaginitis Diagnostics Sales Value, 2020-2031
6.3.2 United States Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Vaginitis Diagnostics Sales Value, 2020-2031
6.4.2 Europe Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Vaginitis Diagnostics Sales Value, 2020-2031
6.5.2 China Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.5.3 China Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Vaginitis Diagnostics Sales Value, 2020-2031
6.6.2 Japan Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Vaginitis Diagnostics Sales Value, 2020-2031
6.7.2 South Korea Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Vaginitis Diagnostics Sales Value, 2020-2031
6.8.2 Southeast Asia Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Vaginitis Diagnostics Sales Value, 2020-2031
6.9.2 India Vaginitis Diagnostics Sales Value by Type (%), 2024 VS 2031
6.9.3 India Vaginitis Diagnostics Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Profile
7.1.2 Abbott Laboratories Main Business
7.1.3 Abbott Laboratories Vaginitis Diagnostics Products, Services and Solutions
7.1.4 Abbott Laboratories Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.1.5 Abbott Laboratories Recent Developments
7.2 Atrida
7.2.1 Atrida Profile
7.2.2 Atrida Main Business
7.2.3 Atrida Vaginitis Diagnostics Products, Services and Solutions
7.2.4 Atrida Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.2.5 Atrida Recent Developments
7.3 Becton, Dickinson and Company
7.3.1 Becton, Dickinson and Company Profile
7.3.2 Becton, Dickinson and Company Main Business
7.3.3 Becton, Dickinson and Company Vaginitis Diagnostics Products, Services and Solutions
7.3.4 Becton, Dickinson and Company Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.3.5 Becton, Dickinson and Company Recent Developments
7.4 Cepheid (Danaher Corporation)
7.4.1 Cepheid (Danaher Corporation) Profile
7.4.2 Cepheid (Danaher Corporation) Main Business
7.4.3 Cepheid (Danaher Corporation) Vaginitis Diagnostics Products, Services and Solutions
7.4.4 Cepheid (Danaher Corporation) Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.4.5 Cepheid (Danaher Corporation) Recent Developments
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 F. Hoffmann-La Roche Ltd. Profile
7.5.2 F. Hoffmann-La Roche Ltd. Main Business
7.5.3 F. Hoffmann-La Roche Ltd. Vaginitis Diagnostics Products, Services and Solutions
7.5.4 F. Hoffmann-La Roche Ltd. Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.6 Hologic, Inc.
7.6.1 Hologic, Inc. Profile
7.6.2 Hologic, Inc. Main Business
7.6.3 Hologic, Inc. Vaginitis Diagnostics Products, Services and Solutions
7.6.4 Hologic, Inc. Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.6.5 Hologic, Inc. Recent Developments
7.7 Laboratory Corporation of America Holdings
7.7.1 Laboratory Corporation of America Holdings Profile
7.7.2 Laboratory Corporation of America Holdings Main Business
7.7.3 Laboratory Corporation of America Holdings Vaginitis Diagnostics Products, Services and Solutions
7.7.4 Laboratory Corporation of America Holdings Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.7.5 Laboratory Corporation of America Holdings Recent Developments
7.8 QIAGEN
7.8.1 QIAGEN Profile
7.8.2 QIAGEN Main Business
7.8.3 QIAGEN Vaginitis Diagnostics Products, Services and Solutions
7.8.4 QIAGEN Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.8.5 QIAGEN Recent Developments
7.9 Quest Diagnostics Incorporated
7.9.1 Quest Diagnostics Incorporated Profile
7.9.2 Quest Diagnostics Incorporated Main Business
7.9.3 Quest Diagnostics Incorporated Vaginitis Diagnostics Products, Services and Solutions
7.9.4 Quest Diagnostics Incorporated Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.9.5 Quest Diagnostics Incorporated Recent Developments
7.10 Quidel Corporation
7.10.1 Quidel Corporation Profile
7.10.2 Quidel Corporation Main Business
7.10.3 Quidel Corporation Vaginitis Diagnostics Products, Services and Solutions
7.10.4 Quidel Corporation Vaginitis Diagnostics Revenue (US$ Million) & (2020-2025)
7.10.5 Quidel Corporation Recent Developments
8 Industry Chain Analysis
8.1 Vaginitis Diagnostics Industrial Chain
8.2 Vaginitis Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Vaginitis Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Vaginitis Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

本レポートと同じKEY WORD(diagnostics)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/04/01 10:27

150.82 円

163.67 円

197.69 円

ページTOPに戻る